Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIFT: Intravenous Thrombolysis in Acute Ischemic Stroke Patients on Factor Xa-inhibitors
NCT06878066Phase 3Recruiting
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator and tenecteplase in ischemic stroke (2 arms). Primary endpoint: Early neurological improvement at 24 hours. Started Mar 2025; status: recruiting.
02
Drugs
tissue-plasminogen activatortenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06878066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878066.